[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 139
1. Chung WC, Kim HK, Yoo JY, Lee JR, Lee KM, Paik CN, Jang UI, Yang JM: Colonic lymphangiomatosis associated with anemia. World J Gastroenterol; 2008 Oct 7;14(37):5760-2
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic lymphangiomatosis associated with anemia.
  • Multiple colonic lymphangioma named as lymphangiomatosis is considered an extremely rare disease.
  • Although lymphangioma is a benign tumor and most colonic lymphangiomas do not cause symptoms and do not require treatment, resection of lymphangioma is necessary in the presence of symptoms such as abdominal pain, bleeding, intussusceptions.
  • We report a case of colonic lymphangiomatosis in a man who presented with abdominal discomfort and anemia, which was diagnosed and treated with endoscopic snare polypectomy.
  • [MeSH-major] Anemia / etiology. Colonic Neoplasms / complications. Lymphangioma / complications

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(2):146-8 [10936792.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):781-4 [11115919.001]
  • [Cites] J Nippon Med Sch. 2001 Jun;68(3):262-5 [11404774.001]
  • [Cites] J Gastroenterol. 2002;37(5):381-6 [12051538.001]
  • [Cites] Surg Today. 2002;32(8):734-7 [12181728.001]
  • [Cites] J Gastroenterol. 2003;38(2):181-5 [12640534.001]
  • [Cites] Am J Dig Dis. 1975 Nov;20(11):1076-80 [1200000.001]
  • [Cites] Arch Surg. 1985 Nov;120(11):1266-9 [4051731.001]
  • [Cites] Radiology. 1994 Sep;192(3):697-702 [8058936.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):252-4 [7789688.001]
  • [Cites] Gastrointest Endosc. 1997 Feb;45(2):204-6 [9041015.001]
  • [Cites] J Clin Gastroenterol. 1997 Apr;24(3):186-7 [9179742.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):383-6 [9412929.001]
  • [Cites] J Gastroenterol. 1999 Aug;34(4):520-4 [10452688.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1747-53 [16133983.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Oct;16(5):530-3 [17004884.001]
  • (PMID = 18837097.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2748215
  •  go-up   go-down


2. Lazaraki G, Tragiannidis D, Xirou P, Nakos A, Pilpilidis I, Katsos I: Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report. Cases J; 2009;2:6462

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report.
  • Lipomas of the colon are benign tumors that rarely occur.
  • They are usually asymptomatic but occasionally they present with clinical manifestations depending on tumor size, localization and complications, which often lead to diagnostic difficulty.
  • During colonoscopy a giant polyp of over 50 mm in its bigger diameter, with a thick stalk of 2 cm, located in the transverse colon, was revealed.
  • In this report discussion over endoscopic resection of colonic lipomas mimicking neoplasms is also performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Nov;30(11):888-93 [3677966.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2826-7 [18270829.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):441-4 [4645612.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jul;5(3):713-21 [8829328.001]
  • [Cites] Surg Endosc. 1998 Jan;12(1):42-5 [9419301.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2143-4 [10950091.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1295-7 [11316189.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1944-6 [11419863.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):929-31 [12024158.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):756-9 [15855988.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):988-90 [16301055.001]
  • [Cites] Indian J Gastroenterol. 2007 Sep-Oct;26(5):254-5 [18227586.001]
  • [Cites] Eur J Surg. 1991 Jan;157(1):51-5 [1675882.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):532-3 [2152245.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):435-8 [2227312.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Am Surg. 1985 Aug;51(8):449-54 [4026070.001]
  • (PMID = 20181161.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827102
  •  go-up   go-down


3. Vilallonga R, Espin Basany E, Armengol M: Cavernous hemangioma: unusual benign tumor of the transverse colon. Turk J Gastroenterol; 2009 Jun;20(2):146-9
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous hemangioma: unusual benign tumor of the transverse colon.
  • Cavernous hemangioma of the colon is an uncommon disease and a rare cause of bleeding.
  • The rectosigmoid is the most common site of this disease in the gastrointestinal tract, while colonic localization is very uncommon.
  • She underwent a colonoscopy and was diagnosed with diffuse cavernous hemangioma of the transverse colon.
  • Colonic hemangiomas are very rare vascular malformations and their clinical presentation is usually acute, recurrent or chronic rectal bleeding.
  • This tumor can be diagnosed as solitary, multiple, or part of a more complex syndrome with cutaneous manifestations.
  • Sometimes, however, recognition of these tumors is difficult and can be a cause of failed surgical treatment and severe complications.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Gastrointestinal Hemorrhage / diagnosis. Hemangioma, Cavernous / diagnosis
  • [MeSH-minor] Aged. Colectomy. Colon / pathology. Colon / radiography. Colon / surgery. Colonoscopy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530050.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


Advertisement
4. Jung SH, Paik CN, Jung JH, Lee KM, Chung WC, Yang JM: Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis. Gut Liver; 2009 Sep;3(3):215-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.
  • Mesenteric fibromatosis (MF) is a rare benign mesenchymal lesion that can occur throughout the gastrointestinal tract, especially small bowel.
  • Its biological behavior is intermediate between benign fibrous tissue proliferation and malignant fibrosarcoma.
  • In previously reported cases of MF, we could find colonic obstruction or ureter obstruction, but simultaneous involvement of colon and ureter was not able to be seen.
  • We described a patient that presented with colonic obstruction and hydroureteronephrosis due to MF at sigmoid colon which mimicked submucosal tumor such as gastrointestinal tumor.
  • This case resulted in a positive positron emission tomography scan suggesting malignant neoplasm, but beta-catenin positivity on immunohistochemical staining separated MF from gastrointestinal stromal tumor and sclerosing mesenteritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5985-8 [18023087.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):924-6 [17205200.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5226-8 [16127758.001]
  • [Cites] Histopathology. 1994 Nov;25(5):469-73 [7532614.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):275-9 [1853806.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):335-41 [2321698.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):93-8 [14750246.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] AJR Am J Roentgenol. 1991 Mar;156(3):539-42 [1899752.001]
  • (PMID = 20431749.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852704
  • [Keywords] NOTNLM ; Colonic obstruction / Hydroureteronephrosis / Mesenteric fibromatosis
  •  go-up   go-down


5. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the indications and use of colonic stents.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


6. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M: Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis; 2009 Jan;30(1):88-92
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer.
  • We reported previously that a new Western-style diet (NWD) for 18 months, consisting of elevated lipids and decreased calcium, vitamin D and methyl-donor nutrients, induced colonic tumors in normal C57Bl/6 mice [Newmark, H.L. et al. (2001) A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice.
  • Carcinogenesis, 22, 1871-1875], suggesting a new mouse model for human sporadic colon cancer.
  • Here, we have extended this study during a longer feeding period of 2 years wherein tumor formation, tumor inhibition by addition of dietary calcium and vitamin D and their effects on gene expression were determined.
  • We also similarly tested individual supplements of methyl donor (transfer) nutrients (folic acid, choline, methionine and dietary fiber), but these had no significant effect on colonic tumor incidence or multiplicity, whereas supplementation with combined calcium and vitamin D produced significant decrease in both colon tumor incidence and multiplicity, during 2 years of feeding.
  • No visible colonic tumors were found at 6 months, very few at 12 months, more at 18 months and significantly at 24 months.
  • In a related study of gene changes of the mouse colonic mucosa at 6 months of feeding taken from this study, long before any tumors were visibly detectable, indicated altered profiles of gene expression linked to later risk of dietary initiation of colon tumor formation.
  • This type of early genetic altered profile, an indication of increased risk of later colonic tumor development, may become a useful tool for prediction of colon tumor risk while the colon grossly still appears histologically and physiologically normal.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1871-5 [11698351.001]
  • [Cites] J Nutr. 1977 Jul;107(7):1340-8 [874577.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7803-10 [18829535.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1586-91 [17556697.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • (PMID = 19017685.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05021
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2722141
  •  go-up   go-down


7. Zimmerman SG, Thorpe LM, Medrano VR, Mallozzi CA, McCartney BM: Apical constriction and invagination downstream of the canonical Wnt signaling pathway require Rho1 and Myosin II. Dev Biol; 2010 Apr 1;340(1):54-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor Adenomatous polyposis coli (APC) is a negative regulator of Wnt signaling and functions in cytoskeletal organization.
  • Disruption of human APC in colonic epithelia initiates benign polyps that progress to carcinoma following additional mutations.
  • Wnt activation is reported to upregulate DE-cadherin in wing discs, and elevated DE-cadherin is thought to promote apical constriction.
  • We find that apical constriction and invagination of APC null tissue are independent of DE-cadherin elevation, but are dependent on Myosin II activity.

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Annu Rev Biochem. 1992;61:721-59 [1497323.001]
  • [Cites] Cell. 1993 Feb 26;72(4):527-40 [8440019.001]
  • [Cites] Development. 1994 Mar;120(3):621-36 [8162860.001]
  • [Cites] C R Acad Sci III. 1993 Sep;316(9):1047-61 [8076205.001]
  • [Cites] EMBO J. 1994 Dec 15;13(24):5826-34 [7813421.001]
  • [Cites] Development. 1996 Jun;122(6):1781-9 [8674417.001]
  • [Cites] Cell. 1996 Nov 29;87(5):833-44 [8945511.001]
  • [Cites] Development. 1997 Feb;124(4):871-80 [9043068.001]
  • [Cites] Cell. 1997 Mar 21;88(6):789-99 [9118222.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1644-9 [9135000.001]
  • [Cites] Nature. 1997 May 15;387(6630):292-5 [9153394.001]
  • [Cites] Development. 1997 Jun;124(11):2255-66 [9187151.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1805-19 [9412474.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1171-82 [9657150.001]
  • [Cites] Dev Cell. 2004 Dec;7(6):871-83 [15572129.001]
  • [Cites] Dev Dyn. 2005 Mar;232(3):685-94 [15712202.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):493-504 [15809032.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):463-73 [15892196.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):357-63 [15925592.001]
  • [Cites] Trends Cell Biol. 2005 Jul;15(7):371-7 [15935670.001]
  • [Cites] Development. 2005 Sep;132(18):4165-78 [16123312.001]
  • [Cites] Development. 2005 Nov;132(22):5033-42 [16236766.001]
  • [Cites] Trends Cell Biol. 2005 Dec;15(12):651-8 [16243528.001]
  • [Cites] Development. 2006 Feb;133(3):547-57 [16396908.001]
  • [Cites] Development. 2006 Mar;133(5):925-35 [16452097.001]
  • [Cites] Nature. 2006 Apr 6;440(7085):798-802 [16598258.001]
  • [Cites] Development. 2006 May;133(9):1683-92 [16554363.001]
  • [Cites] Mol Biol Cell. 2006 May;17(5):2331-45 [16525027.001]
  • [Cites] Development. 2006 Jun;133(12):2407-18 [16720878.001]
  • [Cites] J Cell Sci. 2006 Jun 15;119(Pt 12):2425-34 [16720643.001]
  • [Cites] Development. 2006 Nov;133(21):4257-67 [17021037.001]
  • [Cites] Curr Biol. 2006 Oct 24;16(20):1986-97 [17055977.001]
  • [Cites] Mech Dev. 2007 Mar;124(3):167-79 [17267182.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):910-8 [17192415.001]
  • [Cites] Dev Biol. 2007 May 1;305(1):358-76 [17367777.001]
  • [Cites] Genetics. 2007 Apr;175(4):1741-9 [17277363.001]
  • [Cites] Curr Biol. 2007 Aug 7;17(15):1349-55 [17656094.001]
  • [Cites] Nat Genet. 2007 Nov;39(11):1376-83 [17906625.001]
  • [Cites] Dev Cell. 2007 Nov;13(5):717-29 [17981139.001]
  • [Cites] Dev Cell. 2007 Nov;13(5):730-42 [17981140.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):186-93 [18359618.001]
  • [Cites] Annu Rev Genet. 2008;42:517-40 [18710302.001]
  • [Cites] Cell Stem Cell. 2008 Nov 6;3(5):508-18 [18983966.001]
  • [Cites] Nature. 2009 Jan 22;457(7228):495-9 [19029882.001]
  • [Cites] Development. 2009 Apr;136(8):1283-93 [19279137.001]
  • [Cites] J Cell Sci. 2009 Jun 15;122(Pt 12):2137-48 [19470582.001]
  • [Cites] Development. 2009 Oct;136(19):3205-14 [19736321.001]
  • [Cites] Dev Biol. 2009 Oct 1;334(1):161-73 [19627985.001]
  • [Cites] Cell. 2000 Feb 18;100(4):411-22 [10693758.001]
  • [Cites] Development. 2000 Apr;127(7):1499-508 [10704395.001]
  • [Cites] Nature. 2000 May 4;405(6782):76-81 [10811221.001]
  • [Cites] Nature. 2000 May 4;405(6782):81-5 [10811222.001]
  • [Cites] Development. 2000 Aug;127(16):3607-17 [10903184.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1194-7 [10947987.001]
  • [Cites] Cell. 2001 Apr 6;105(1):81-91 [11301004.001]
  • [Cites] Bioessays. 2001 Aug;23(8):691-7 [11494317.001]
  • [Cites] Curr Biol. 2002 Jan 22;12(2):95-104 [11818059.001]
  • [Cites] Development. 2002 Apr;129(7):1751-62 [11923210.001]
  • [Cites] Development. 2002 Jun;129(11):2565-76 [12015286.001]
  • [Cites] Dev Biol. 2002 Oct 1;250(1):91-100 [12297098.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3819-25 [12839979.001]
  • [Cites] Development. 2003 Dec;130(26):6533-43 [14660542.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):949-61 [14662741.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Development. 2004 Jul;131(14):3273-83 [15226252.001]
  • [Cites] Nat Cell Biol. 2004 Sep;6(9):820-30 [15311282.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] Development. 1990 Sep;110(1):73-84 [2081472.001]
  • [Cites] Development. 1991 Jan;111(1):1-14 [1901784.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1568-76 [1884999.001]
  • (PMID = 20102708.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073891; United States / NIGMS NIH HHS / GM / R01 GM073891-01A2; United States / NIGMS NIH HHS / GM / R01 GM073891-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Drosophila Proteins; 0 / Wnt Proteins; EC 3.6.1.- / Myosin Type II; EC 3.6.5.2 / Rho1 protein, Drosophila; EC 3.6.5.2 / rho GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS181691; NLM/ PMC4056678
  •  go-up   go-down


8. Scherer K, Johnston J, Panda M: Dural based mass: malignant or benign. J Radiol Case Rep; 2009;3(11):1-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural based mass: malignant or benign.
  • In March 2007, a 68 year old female was diagnosed with colonic adenocarcinoma metastatic to the lungs and a frontoparietal parafalcine lesion suspected to be a meningioma was also noted.
  • Pathology indicated metastatic adenocarcinoma with colonic primary without evidence of meningioma.
  • Dural metastatic tumors mimicking meningiomas is an uncommon phenomenon, particularly when the primary location is the colon.
  • This paper additionally discusses the differentiation of benign dural based tumors like meningiomas from malignant findings.
  • Multiple adjunct studies can differentiate meningiomas from metastatic tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Dec;33(12):1211-26 [12514791.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):317-20 [15253548.001]
  • [Cites] Acta Cytol. 1981 Sep-Oct;25(5):461-79 [7025541.001]
  • [Cites] Acta Cytol. 1981 Nov-Dec;25(6):599-610 [6947665.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Neurosurg Sci. 1987 Jan-Mar;31(1):33-6 [3625287.001]
  • [Cites] Neuroradiology. 1993;35(4):272-3 [8492892.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Feb;34(2):108-10 [7514757.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):241-5 [12480230.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):193-9 [12187955.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):880-7 [11419971.001]
  • [Cites] Australas Radiol. 2005 Dec;49(6):497-500 [16351616.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):135-7 [9213059.001]
  • [Cites] Neurologist. 2006 Jan;12(1):48-52 [16547447.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] Neurochirurgie. 1999 May;45(2):160-3 [10448659.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):552-8 [9761048.001]
  • (PMID = 22470624.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303278
  • [Keywords] NOTNLM ; Dural based mass / meningioma / metastatic dural based lesions
  •  go-up   go-down


9. Zmora O, Benjamin B, Reshef A, Neufeld D, Rosin D, Klein E, Ayalon A, Shpitz B: Laparoscopic colectomy for colonic polyps. Surg Endosc; 2009 Mar;23(3):629-32
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colonic polyps.
  • BACKGROUND: Benign colonic polyps not amenable to colonoscopic resection or those containing carcinoma require surgical excision.
  • The aim of this study was to review our experience with the laparoscopic approach for retrieval of colonic polyps with specific emphasis on safety, feasibility, and tumor localization.
  • METHODS: Retrospective chart review of all patients who underwent laparoscopic colectomy for colonic polyps was performed.
  • RESULTS: Forty-nine patients (22 males, 27 males, mean age 66 years) underwent laparoscopic colectomy for colonic polyps.
  • Indications for surgery were presumably benign polyps in 38 patients, and superficial carcinoma in a polyp, diagnosed by colonoscopy, in 11; twenty-three patients underwent preoperative localization procedures.
  • In 7 of the 38 patients with presumably benign lesion, colon cancer was diagnosed in the colectomy specimen.
  • CONCLUSIONS: Laparoscopic surgery for the treatment of colonic polyps seems to be feasible and safe, with a low complication rate.
  • Tumor localization is crucial for adequate resection.
  • Although one-fifth of presumably benign polyps harbored cancer, none of these patients had positive lymph nodes.
  • [MeSH-major] Colectomy / methods. Colonic Polyps / surgery. Laparoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067054.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


10. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • Furthermore, MR colography evaluating the rest of the colon past the stenosis was possible with all patients.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • Furthermore, the potential is big in performing a full preoperative colon evaluation even in patients with obstructing cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


11. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • However, GATA-4 is not expressed in normal adult colonic mucosa.
  • Its protein expression in colonic adenocarcinoma has not been systematically evaluated and small number of samples was previously reported as negative.
  • Nuclear factor-B (NF-B) activation was shown to promote the growth of the colon tumors in experimental models and was correlated with tumor angiogenesis and progression in human colorectal cancer.
  • The benign colonic mucosa and the matching metastatic tumors of the same patients were also included in the study.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • NF-B activation was not present in any of the samples of benign colonic mucosa, but it was detected in 64% adenocarcinomas (p<0.0001, Chi-Square).
  • CONCLUSIONS: GATA-4, a developmental transcription factor is not expressed by normal colonic mucosa, but is present in 1/5 of primary tumors that gave rise to distant metastases and in almost 1/2 of their respective metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Eriksen JR, Ibsen PH, Gyrtrup HJ: [Granular cell tumor of the colon--Abrikossoff's tumor]. Ugeskr Laeger; 2006 May 22;168(21):2080-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granular cell tumor of the colon--Abrikossoff's tumor].
  • [Transliterated title] Granularcelletumor i colon--Abrikossoffs tumor.
  • A 50-year-old woman had a right hemicoletomy due to a large sessile polyp in the ascending colon, inappropriate for polypectomy.
  • Histopathologic examination of the specimen showed a tubulovillous adenoma with moderate dysplasia and an adjacent 1 x 1 cm submucosal tumor classified as a benign GCT due to the appearance in the light microscope and immunohistochemical analysis.
  • To our knowledge, this is the first reported case of synchronic adenoma and GCT in the colon.
  • To date there is no evidence of any association or disposing factors between GCT in the colon and colonic adenomas or malignancy.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Granular Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768929.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


14. Hajdú N, Zsoldos P, Neuberger G: [Rectum tumor diagnosed by subcutaneous emphysema of the chest]. Magy Seb; 2009 Oct;62(5):308-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectum tumor diagnosed by subcutaneous emphysema of the chest].
  • BACKGROUND: Various benign and malignant thoracic or abdominal diseases can cause subcutaneous emphysema on the chest, pneumomediastinum or pneumopericardium.
  • To date only 7 cases have been reported on perforation of the sigmoid colon or the rectum presenting with these rare symptoms.
  • Further examination revealed that this was caused by a rectal tumor causing large bowel obstruction and a consequent perforation of the transverse colon.
  • [MeSH-major] Colonic Diseases / surgery. Intestinal Obstruction / surgery. Rectal Neoplasms / complications. Rectal Neoplasms / diagnosis. Subcutaneous Emphysema / etiology


15. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology; 2009 Jan;136(1):206-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
  • The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined.
  • RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208).
  • Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
  • [MeSH-major] Colorectal Neoplasms / etiology. Tumor Suppressor Proteins / physiology. ras GTPase-Activating Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Disease Progression. Female. Gene Silencing. Genes, ras. Humans. Male. Middle Aged. Signal Transduction


16. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med; 2009 Aug;133(8):1317-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.
  • CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653732.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


17. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


18. Weinstein A, Nouri K, Bassiri-Tehrani S, Flores F, Jimenez G: Muir-Torre syndrome: a case of this uncommon entity. Int J Dermatol; 2006 Mar;45(3):311-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to BCC, she had been treated for breast cancer, colon cancer, and cervical cancer prior to emigrating to the USA.
  • Her colonic malignancy had been localized proximal to the splenic flexure.
  • She also had a history of colonic polyps and distal colonic villous adenoma.
  • Her family history was significant for a sister with colon cancer and transitional cell carcinoma of the urinary bladder.
  • No further treatment was required for these benign sebaceous tumors, but their presence defined our patient's condition as Muir-Torre syndrome.
  • Mohs' micrographic surgery was performed on the tragus BCC and the margins were tumor free in one stage.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Basal Cell / complications. Colonic Neoplasms / complications. Skin Neoplasms / complications. Uterine Cervical Neoplasms / complications


19. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL: Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc; 2009 Feb;23(2):409-15
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are increased after surgery and may stimulate tumor growth after cancer resection.
  • This study's purpose was to determine the impact of open and minimally invasive (MIS) colorectal resection (CR) for benign indications on plasma Ang 1 and 2 levels.
  • CONCLUSION: CR for benign pathology results in higher Ang 2 levels, lower Ang 1 levels, and lower Ang 1 to Ang 2 ratios early after surgery.
  • These results, plus the already noted VEGF increases, suggest that surgery results in proangiogenic plasma protein changes that may stimulate tumor growth early after surgery.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-2 / blood. Colectomy. Colonic Diseases / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Surg Endosc. 2009 Feb;23(2):416. Kallady, M [corrected to Kalady, M]
  • (PMID = 18813991.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2
  •  go-up   go-down


20. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


21. Consolo P, Luigiano C, Pellicano R, Ferrara F, Giacobbe G, Morace C, Pallio S, Tortora A, Melita G, Bassi M, D'Imperio N, Alibrandi A, Familiari L: Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size. Minerva Med; 2010 Oct;101(5):311-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size.
  • The most frequent type of neoplasm was villous adenoma (76.1%).
  • CONCLUSION: ER is a safe and effective procedure for removing benign appearing very large colorectal neoplasms.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Hemostasis, Surgical / methods. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / therapy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Minerva Med. 2011 Apr;102(2):XV. Giuseppinella, M [corrected to Melita, G]
  • (PMID = 21048553.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Zwielly A, Mordechai S, Sinielnikov I, Salman A, Bogomolny E, Argov S: Advanced statistical techniques applied to comprehensive FTIR spectra on human colonic tissues. Med Phys; 2010 Mar;37(3):1047-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced statistical techniques applied to comprehensive FTIR spectra on human colonic tissues.
  • PURPOSE: Colon cancer is a major public health problem due to its high disease rate and death toll worldwide.
  • In the present study, the authors investigated the potential of FTIR microscopy to define spectral changes among normal, polyp, and cancer human colonic biopsied tissues.
  • METHODS: A large database of FTIR microscopic spectra was compiled from 230 human colonic biopsies.
  • The database was divided into five subgroups: Normal, cancerous tissues, and three stages of benign colonic polyps, namely, mild, moderate, and severe polyps, which are precursors of carcinoma.
  • These results strongly support the potential of developing FTIR microscopy as a simple, reagent-free tool for early detection of colon cancer and, in particular, for discriminating among the benign premalignant colonic polyps having increasing degrees of dysplasia severity (mild, moderate, and severe).
  • [MeSH-major] Algorithms. Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Colonic Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Spectroscopy, Fourier Transform Infrared / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384240.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Oldenburg A, Albrecht T: [Baseline and contrast-enhanced ultrasound of the liver in tumor patients]. Ultraschall Med; 2008 Oct;29(5):488-98
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
  • Conventional sonography is the most commonly used modality for liver imaging in tumor patients.
  • The majority of liver metastases are hypoechoic and well defined in baseline ultrasound (US), while detection of isoechoic or small liver metastases <1 cm is difficult and the differentiation of liver metastases from benign liver lesions and other malignant liver tumors can be impossible with baseline US.
  • Furthermore, the typical enhancement patterns of the different benign and malignant liver lesions allow reliable characterization and differentiation from liver metastases in the majority of cases.
  • This paper provides information about the advantages and expedient application of contrast-enhanced ultrasound (CEUS) in tumor patients.
  • [MeSH-major] Contrast Media. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Colonic Neoplasms / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neovascularization, Pathologic / ultrasonography. Reproducibility of Results. Sarcoma, Ewing / pathology. Sarcoma, Ewing / ultrasonography. Ultrasonography, Doppler / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ultraschall Med. 2009 Apr;30(2):125-7 [19340726.001]
  • (PMID = 19241505.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


24. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested that the human counterpart of Prospero, PROX1, acts similarly in human cancers.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
  • Our data underscore the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through the regulation of cell polarity and adhesion.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / AICR/ 09-0791; United Kingdom / Medical Research Council / / MRC/ G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


25. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion.
  • Colonic polyps are common both in adults and children; however, the malignant potential varies according to the type of polyp.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • The association of CSM with benign juvenile polyps and the absence of histologic markers for increased replication and malignant transformation support the notion that this endoscopic finding is not preneoplastic.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Intestinal Mucosa / pathology. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. Chen YY, Soon MS: Preoperative diagnosis of colonic angiolipoma: a case report. World J Gastroenterol; 2005 Aug 28;11(32):5087-9
Hazardous Substances Data Bank. Barium, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of colonic angiolipoma: a case report.
  • Angiolipoma, a common benign tumor mostly seen in the subcutaneous tissue, is a rare pathological condition in the gastrointestinal tract that is usually diagnosed postoperatively.
  • [MeSH-major] Angiolipoma / radiography. Colonic Neoplasms / radiography. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124075.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 24GP945V5T / Barium
  • [Other-IDs] NLM/ PMC4321939
  •  go-up   go-down


27. Ghossain MA, Chucrallah A, Kanso H, Aoun NJ, Abboud J: Multilocular adenomatoid tumor of the ovary: ultrasonographic findings. J Clin Ultrasound; 2005 Jun;33(5):233-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilocular adenomatoid tumor of the ovary: ultrasonographic findings.
  • We report the sonographic findings of a rare benign ovarian tumor in a 69-year-old woman.
  • Surgery revealed an adenomatoid tumor.
  • Adenomatoid tumors are benign lesions of mesothelial origin, usually solid in nature and rarely located in the ovaries. (c) 2005 Wiley Periodicals, Inc.
  • [MeSH-major] Adenomatoid Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Female. Humans. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. J Clin Ultrasound 33:233-236, 2005.
  • (PMID = 16047378.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One; 2010;5(10)
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability.
  • Based on a consensus of the results obtained by two normalization algorithms, and two probe set sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between normal and tumor samples and between benign and malignant tumors, respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis. Oncogenes. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):395-401 [11687950.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Gut. 2003 Aug;52(8):1148-53 [12865273.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):323-31 [14960458.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):335-51 [10448282.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):480-6 [15685558.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):517-24 [15706427.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] BMC Bioinformatics. 2005;6:80 [15799785.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] Expert Rev Mol Diagn. 2006 May;6(3):465-80 [16706747.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1829-36 [16721809.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):872-82 [16924468.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6998-7006 [17109495.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):103-37 [17010523.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Cancer Detect Prev. 2007;31(4):282-95 [17936523.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] Mol Cancer. 2007;6:79 [18081933.001]
  • [Cites] BMC Bioinformatics. 2008;9:140 [18318917.001]
  • [Cites] BMC Bioinformatics. 2008;9:164 [18366762.001]
  • [Cites] Surg Clin North Am. 2008 Aug;88(4):681-704, v [18672136.001]
  • [Cites] Dis Markers. 2008;25(1):1-16 [18776587.001]
  • [Cites] Nat Biotechnol. 2008 Sep;26(9):1003-10 [18711341.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45 [18843029.001]
  • [Cites] World J Gastroenterol. 2008 Oct 14;14(38):5887-92 [18855989.001]
  • [Cites] Biotechniques. 2008 Nov;45(5):501-20 [19007336.001]
  • [Cites] Cell Oncol. 2009;31(1):19-29 [19096147.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):201-9 [19081199.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):165-75 [19328798.001]
  • [Cites] J Biomed Inform. 2009 Aug;42(4):605-11 [19535009.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Sep;9(6):623-30 [19732006.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):765-73 [20087348.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):41-56 [17210682.001]
  • [ErratumIn] PLoS One. 2010;5(12) doi: 10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca. Ostrowsk, Jerzy [corrected to Ostrowski, Jerzy]
  • (PMID = 20957034.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948500
  •  go-up   go-down


29. Cervantes-Solís C, Jiménez-González A, Zamora-Nava LE, Torre-Delgadillo A: [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital]. Rev Gastroenterol Mex; 2010;75(2):158-64
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital].
  • [Transliterated title] Engrosamiento colónico y de íleon terminal documentado por tomografía computarizada y su correlación con hallazgos colonoscópicos en un hospital de tercer nivel.
  • BACKGROUND: Tomographic finding of thickening of colon and terminal ileum and its correlation with colonoscopic findings has been poorly studied.
  • Various radiographic patterns of intestinal thickening suggestive of benign disease have been described, but they cannot completely rule out malignancy.
  • OBJECTIVE: To determine if a relationship exists between colonic wall or terminal ileum thickening documented by computed tomography with abnormal colonoscopic findings and colon cancer.
  • METHODS: Retrospective study of radiology database of a tertiary hospital identifying patients with report of thickening of terminal ileum or colon and have colonoscopy performed.
  • The main site of colonic thickening on CT was sigmoid in 8 (33.3%) cases.
  • The most common colonoscopic finding was colorectal tumor probably malignant in 7 (29.2%) patients, but adenocarcinoma was reported in 8 (33.3%) patients.
  • There was a statistically significant relationship between colonic thickening and colorectal cancer (p < 0.001) but no statistically significant association was found between thickening and sigmoid colon cancer.
  • CONCLUSIONS: The finding of thickening of colon documented by computed tomography is significantly associated with the presence of colorectal carcinoma.
  • [MeSH-major] Colon / pathology. Colon / radiography. Colonic Neoplasms / diagnosis. Colonoscopy. Ileum / pathology. Ileum / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20615783.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


30. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
  • Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal beta-oxidation of phytol-derived, branched-chain fatty acids from red meat and dairy products -- suspected risk factors for colon carcinoma (CCa).
  • AMACR was first found overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
  • [MeSH-major] Colon / enzymology. Colonic Neoplasms / genetics. CpG Islands / genetics. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Racemases and Epimerases / genetics
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


31. Abdul M, Mccray SD, Hoosein NM: Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol; 2008;47(8):1546-50
Hazardous Substances Data Bank. PICROTOXIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, we have investigated, by immunohistochemistry, GABAar levels in 12 normal human prostate, 13 benign prostatic hyperplasia (BPH) and 148 human prostate cancer specimens.
  • [MeSH-minor] Bicuculline / pharmacology. Cell Proliferation / drug effects. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Dihydroergotoxine / pharmacology. GABA Agonists / pharmacology. GABA Antagonists / pharmacology. GABA-A Receptor Agonists. GABA-B Receptor Agonists. Humans. Isonicotinic Acids / pharmacology. Male. Picrotoxin / pharmacology. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Receptors, GABA-B / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607852.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR16461
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA Antagonists; 0 / GABA-A Receptor Agonists; 0 / GABA-B Receptor Agonists; 0 / Isonicotinic Acids; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B; 11032-41-0 / Dihydroergotoxine; 124-87-8 / Picrotoxin; Y37615DVKC / Bicuculline; YTF580771Y / isoguvacine
  •  go-up   go-down


32. Lebeau R, Koffi E, Diané B, Amani A, Kouassi JC: [Acute intestinal intussusceptions in adults: analysis of 20 cases]. Ann Chir; 2006 Oct;131(8):447-50
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Invaginations intestinales aiguës de l'adulte: analyse d'une série de 20 cas.
  • The clinical and radiological findings were suggestive of bowel obstruction (N = 14), peritonitis (N = 5) and appendicular abscess (N = 1).
  • Necrosis was found in the intussusceptum in 10 cases and a tumor on the lead point in 14 cases (5 benign lesions and 9 malignant ones).
  • For intussusception involving the colon, all patients underwent en bloc resection with immediate anastomosis, while intussusception located on the small bowel were treated by surgical reduction (N = 1), en bloc resection (N = 8) with immediate (N = 7) or delayed (N = 1) anastomosis.
  • En bloc resection is recommended because of the frequency of neoplasms and bowel ischemia.
  • [MeSH-major] Colonic Diseases / surgery. Ileal Diseases / surgery. Ileocecal Valve. Intussusception / surgery. Jejunal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765901.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Ghidirim G, Mishin I, Gutsu E, Gagauz I, Danch A, Russu S: Giant submucosal lipoma of the cecum: report of a case and review of literature. Rom J Gastroenterol; 2005 Dec;14(4):393-6
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoma of the colon is a relatively rare benign tumor.
  • A case with intermittent subacute colon obstruction due to a giant lipoma of the cecum is reported.
  • 7 cm in diameter) polypoid mass occluding the lumen of the cecum and the ascending colon.
  • Colonoscopy revealed a submucosal mass suspected of benign tumor but too large for endoscopic resection.
  • Surgery revealed a hard elongated mass in the right colon, which telescoped into the transverse colon and caused colo-colonic intussusception.
  • Along with a review of the literature, the incidence, diagnosis complications and treatment of colonic lipomas are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400357.001).
  • [ISSN] 1221-4167
  • [Journal-full-title] Romanian journal of gastroenterology
  • [ISO-abbreviation] Rom J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


34. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M: Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun; 2005 Jul 8;332(3):800-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer.
  • Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells.
  • COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry.
  • Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition.
  • Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / biosynthesis. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Membrane Proteins. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907789.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 69533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


35. Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res; 2005 Feb 15;11(4):1521-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of tumor-specific CD8(+) T cells in patients with breast and head and neck cancer.
  • We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.
  • EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.
  • We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.
  • Tumors with higher level of cyclin B1 expression elicit higher anti-cyclin B1 antibody levels.
  • Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.
  • Immune responses to aberrantly expressed cyclin B1 in tumors and premalignant lesions should be further explored as diagnostic and prognostic markers, in addition to their immunotherapeutic potential.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism. Male. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746055.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 090440
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  •  go-up   go-down


36. Gold DV, Stein R, Burton J, Goldenberg DM: Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol; 2010;4(1):1-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.
  • For PanIN lesions there was greater expression of CD74 within higher grade, PanIN-3 lesions, whereas the colonic adenomas showed no such trend, but overall, a higher frequency and intensity of CD74 labeling than was observed within the colon carcinomas.
  • These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Humans. Immunohistochemistry. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1481-9 [15923369.001]
  • [Cites] Cancer Lett. 2001 Jul 10;168(1):87-91 [11368882.001]
  • [Cites] Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44 [11439146.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1512-8 [12900767.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):592-8 [12827305.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5546-50 [15313888.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6606-11 [15475450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(24):7395-9 [6324166.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4568-77 [2663143.001]
  • [Cites] Nature. 1990 Jun 14;345(6276):615-8 [2190094.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2391-6 [1527384.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2419-26 [16638847.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6794-801 [16709839.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4807-16 [16484589.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s [17875789.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2784-92 [18056708.001]
  • [Cites] Infect Immun. 2008 Jul;76(7):3233-40 [18474653.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2808-17 [19351768.001]
  • [Cites] Eur J Cancer. 2009 Jun;45(9):1654-63 [19269807.001]
  • [Cites] World J Gastroenterol. 2009 Jun 21;15(23):2855-61 [19533806.001]
  • [Cites] World J Gastroenterol. 2010 Jul 14;16(26):3258-66 [20614481.001]
  • [Cites] J Neurooncol. 2010 Nov;100(2):177-86 [20443131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8581-5 [8397411.001]
  • [Cites] Nature. 1994 Apr 7;368(6471):551-4 [8139689.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):64-71 [8540610.001]
  • [Cites] Biochem J. 1996 Nov 15;320 ( Pt 1):293-300 [8947500.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 [9192661.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):32-6 [10431843.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3705-11 [15297317.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1254-61 [15477757.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):171-6 [15972644.001]
  • [Cites] Immunology. 1999 Oct;98(2):296-302 [10540230.001]
  • (PMID = 21228923.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096924
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II; 0 / invariant chain
  • [Other-IDs] NLM/ PMC3016099
  • [Keywords] NOTNLM ; CD74 / colon carcinoma / gastric carcinoma / invariant chain / pancreatic carcinoma
  •  go-up   go-down


37. Steff M, Bourillon A, Frebourg T, Balderi X, Descamps V, Joly P, Piette F, Crestani B, Grandchamp B, Soufir N: [Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]. Ann Dermatol Venereol; 2010 Mar;137(3):203-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Variation phénotypique intra- et interfamiliale dans le syndrome de Birt-Hogg-Dubé : conséquences sur la prise en charge.
  • BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is an autosomal-dominantly inherited genodermatosis that predisposes to the development of benign hair follicle tumours, lung cysts, kidney tumours, and possibly colonic cancers, due to mutations in the FLCN gene.
  • The first proband showed fibrofolliculomas (FF), a history of pneumothorax and colonic adenoma.
  • [MeSH-major] Frameshift Mutation. Hair Follicle / pathology. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Colonic Neoplasms / genetics. Emphysema / genetics. Female. Hair Diseases / genetics. Humans. Male. Middle Aged. Pedigree. Phenotype. Pneumothorax / genetics. Sequence Analysis, Protein

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Masson SAS.
  • (PMID = 20227563.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


38. Goasguen N, Cattan P, Godiris-Petit G, Munoz-Bongrand N, Allez M, Lemann M, Sarfati E: [Colonic lipoma: case report and literature review]. Gastroenterol Clin Biol; 2008 May;32(5 Pt 1):521-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic lipoma: case report and literature review].
  • [Transliterated title] Lipome colique : cas clinique et revue de la littérature.
  • Colonic lipoma is a rare benign tumor infrequently met in clinical practice.
  • We report a case of symptomatic lipoma of the ascending colon in a 61-year-old woman.
  • [MeSH-major] Colonic Neoplasms. Lipoma

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343069.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 33
  •  go-up   go-down


39. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


40. Saad RS, Silverman JF, Khalifa MA, Rowsell C: CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol; 2009 May;17(3):196-201
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CK20/CK7 immunoprofile of colorectal adenocarcinoma has been described in studies, which have mostly lumped colonic and rectal tumors together.
  • CDX2 showed moderate-strong positivity in all cases and was not related to tumor differentiation.
  • Benign rectal mucosa was available in 37 cases and showed the following results: CK7-/CK20+ in 25/37 (67%), CK7+/CK20+ in 8/37 (22%) and CK7-/CK20- in 4/37 (11%) cases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):464
  • (PMID = 19098678.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


41. Hatano K, Fujita S, Tsujimoto Y, Takada T, Honda M, Tsujimoto M, Matsumiya K, Fujioka H: Rare case of the hyaline vascular type of Castleman's disease of the kidney. Int J Urol; 2007 Dec;14(12):1098-100
Genetic Alliance. consumer health - Kidney Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Castleman's disease (CD) is a rare disorder characterized by a benign proliferation of lymphoid tissue.
  • We herein report a rare case of CD presenting as a left renal tumor.
  • A 70-year-old male was examined by computed tomography for a follow-up for colonic diverticulitis and a left renal mass measuring 2.0 cm in diameter was incidentally found.
  • Based on our findings, CD should be included in the differential diagnosis of renal tumors.

  • Genetic Alliance. consumer health - Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036051.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


42. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • In HCA7 colon and C4-2 prostate carcinoma cells, ERBB2 is constitutively activated in a ligand-independent manner, whereas IGF1R-beta and PDGFR-beta require ligand interaction for activation.
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959784.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA073839; United States / NCI NIH HHS / CA / CA082867; United States / NCRR NIH HHS / RR / P20 RR016434; United States / NCRR NIH HHS / RR / P20 RR017698
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


43. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512601.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 192
  •  go-up   go-down


44. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • The established murine colon epithelial cell line provides a useful experimental model to further elaborate genetic and epigenetic factors that may promote or inhibit colon tumorigenesis and metastasis.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


45. Moussi A, Nouira R, Bourguiba B, Daldoul S, Zaouche A: A rare cause of lower gastrointestinal bleeding. Tunis Med; 2010 Dec;88(12):961-3
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyoma of the colon are rare benign smooth muscle tumours.
  • The colonoscopy showed an active bleeding from the right colon but it was enable to specify the nature and the exact seat of the bleeding lesion.
  • An emergent operation showed a tumor of the right colic angle of 8 cm.
  • CONCLUSION: Colic leiomyomas are rare benign tumours.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Leiomyoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21136371.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


46. Boni L, Dionigi G, Cassinotti E, Di Giuseppe M, Diurni M, Rausei S, Cantore F, Dionigi R: Single incision laparoscopic right colectomy. Surg Endosc; 2010 Dec;24(12):3233-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery has been fully validated as alternative, minimally invasive treatment for different benign and malignant conditions.
  • METHODS: After signed, informed consent was obtained, patients with malignant tumors or large polyps of the right colon underwent single-incision colonic resection through a 3-cm incision using two different single-port devices and articulated or coaxial curved instruments.
  • The mean postoperative stay was 5 ± 1.2 days (range, 4-14), and mean lymph node retrieval and tumor-free margins was 24 ± 7 (range, 29-15) and 8 ± 3 (range, 6-12) cm, respectively.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464415.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Merenda R, Portale G, Galeazzi F, Tosolini C, Sturniolo GC, Ancona E: Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis. Tumori; 2008 Nov-Dec;94(6):882-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal polyposis is the main feature of familial adenomatous polyposis (FAP), but benign and malignant lesions have also been described in the stomach, duodenum, small bowel, biliary tract and pancreas.
  • This report described the rare case of a patient presenting with duodenal adenomas with dysplastic changes and tumor infiltration as the first sign of FAP, who was treated by pancreaticoduodenectomy followed by proctocolectomy for subsequent dysplastic changes in colonic polyps.
  • [MeSH-major] Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Colonic Polyps / pathology. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy


48. Ohta Y, Saitoh K, Akai T, Uesato M, Ochiai T, Matsubara H: Early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma: report of a case. Surg Today; 2008;38(8):756-60
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma: report of a case.
  • We herein report a case of early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma.
  • A 65-year-old man with a 5-year history of diabetes mellitus and benign prostatic hypertrophy was admitted to our hospital to undergo a resection of sigmoid colon carcinoma in December 2000.
  • Upper gastrointestinal endoscopy, which was performed as routine preoperative screening, revealed an elevated submucosal-tumor-like lesion with a shallow central depression in the anterior wall of the duodenal bulb.
  • The histopathology of the resected duodenal specimen revealed the tumor to be an adenocarcinoma arising from Brunner's glands.
  • [MeSH-major] Brunner Glands / pathology. Brunner Glands / surgery. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Colonic Neoplasms / surgery. Duodenal Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668323.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


49. Lowe DL, Chaudhary AJ, Lee JR, Chamberlain SM, Schade RR, Cuartas-Hoyos U: Four cases of patients with gastrointestinal granular cell tumors. South Med J; 2007 Mar;100(3):298-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of patients with gastrointestinal granular cell tumors.
  • We present four cases of gastrointestinal granular cell tumors (GCT) with a literature review.
  • Gastrointestinal granular cell tumors, a benign neural tumor thought to arise from Schwann cells, can occur in several areas, including the gastrointestinal tract.
  • Although most GCTs are benign and can be followed endoscopically without resection, the malignant potential warrants evaluation with endoscopic ultrasound for possible endoscopic or surgical resection.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Esophageal Neoplasms / diagnosis. Granular Cell Tumor / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396735.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


50. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • In normal stomach and colon, beta3Gn-T6 was strongly expressed in the Golgi region of epithelia.
  • Tissue specimens from a familial adenomatous polyposis patient showed a clear correlation between the down-regulation of beta3Gn-T6 expression and the degree of dysplasia/neoplasia.
  • These results suggested that the expression of beta3Gn-T6 is closely regulated during differentiation and dedifferentiation. beta3Gn-T6 would be a useful marker for distinguishing between benign adenomas and premalignant lesions.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. N-Acetylglucosaminyltransferases / genetics. N-Acetylglucosaminyltransferases / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


51. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


52. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate markers in colon carcinoma.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • Glycoconjugate markers for colon cancer include aberrant: mucins covering the surface of the colon epithelial cells, cadherins, selectins and Ig-like adhesion molecules mediating cell-cell adhesion, integrins and integral membrane proteoglycans responsible for adhesion of colon epithelial cells to extracellular matrix, glycoconjugate components of ECM, as well as lysosomal membrane glycoproteins and exoglycosidases.
  • Detection of colon cancer at early non malignant stage is crucial in its prevention and eradication.
  • As colon cancer is the effect of accumulation many somatic mutations in oncogens, supressors, mismatch repair genes and many genes responsible for posttranslational modifications of proteins, multidirectional approach should be applied for its detection.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


53. Alinger B, Kiesslich T, Datz C, Aberger F, Strasser F, Berr F, Dietze O, Kaserer K, Hauser-Kronberger C: Hedgehog signaling is involved in differentiation of normal colonic tissue rather than in tumor proliferation. Virchows Arch; 2009 Apr;454(4):369-79
Hazardous Substances Data Bank. CYCLOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling is involved in differentiation of normal colonic tissue rather than in tumor proliferation.
  • It is also present in adult tissues and unusual expression has been associated with formation of benign and malignant lesions.
  • We examined the presence of the Hedgehog pathway in normal and pathological human colon tissue.
  • Pathological tissue samples comprised 23 benign and 20 malignant lesions of human colon.
  • The influence of the Hedgehog pathway on differentiation and proliferation has been investigated by analyzing the effect of the pathway inhibitor Cyclopamine on human colon cancer cell lines HT29 and CaCo2.
  • In normal colon, we detected expression of Shh and Dhh within the lining epithelium and Patched, Gli1, and Gli2 along the whole crypts.
  • Within all benign lesions, positive staining of Shh, Dhh, Gli1, Gli2, and Ptch was detected.
  • We conclude that Hedgehog signaling is involved rather in constant differentiation and renewing of the colonic lining epithelium than in cancer formation, growth, or proliferation.
  • [MeSH-major] Cell Differentiation / physiology. Colonic Neoplasms / metabolism. Hedgehog Proteins / metabolism. Intestinal Mucosa / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Transformation, Neoplastic / metabolism. Colon / cytology. Colon / drug effects. Colon / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Veratrum Alkaloids / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280222.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / FWF/ P 20652
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  •  go-up   go-down


54. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 38 cases (peritoneal endometriosis (n=14), gastrointestinal endometriosis (n=21: 11 colon, 8 appendix, 2 small bowel), and 3 cases of endometrioid carcinoma arising in colonic endometriosis (n=3)) were included in the study.
  • All three cases of carcinoma arising in colonic endometriosis showed a total loss of N-cadherin in the tumor, but preserved E-cadherin and beta-catenin expression.
  • In these cases, areas of benign endometriotic glands near the tumor showed weak and focal N-cadherin expression that was gradually lost.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898423.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


55. Campos FG, Valarini R: Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):249-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign diseases were diagnosed in 2356 patients (49.6%).
  • Most diseases were located in 50.7% of the left and sigmoid colon, 28.2% in the rectum and anal canal, 8.0% in the right colon, and diffuse 7.0%.
  • Two thousand three hundred and eighty-nine (50.4%) malignant tumors were operated upon, and histologic classification showed 2347 (98%) adenocarcinomas, 30 (0.6%) spinocelular carcinomas, and 12 (0.2%) other histologic types.
  • Tumor recurrence rate was 16.3% among patients followed more than 1 year.
  • (2) operative indications for benign and malignant diseases were similar, and diverticular disease of the colon comprised 40% of the benign ones;.
  • [MeSH-major] Colectomy / utilization. Colonic Diseases / surgery. Laparoscopy / utilization. Registries

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542856.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Jost RS, Jost R, Schoch E, Brunner B, Decurtins M, Zollikofer CL: Colorectal stenting: an effective therapy for preoperative and palliative treatment. Cardiovasc Intervent Radiol; 2007 May-Jun;30(3):433-40
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To demonstrate the effectiveness of preoperative and palliative colorectal stent placement in acute colonic obstruction.
  • METHODS: Sixty-seven consecutive patients (mean age 67.3 years, range 25-93 years) with clinical and radiological signs of colonic obstruction were treated: 45 (67%) preoperatively and 22 (33%) with a palliative intent.
  • In 59 patients (88%) the obstruction was malignant, while in 8 (12%) it was benign.
  • The improved general condition and adequate bowel cleansing allowed single-stage tumor resection and primary end-to-end anastomosis without complications in 31 cases (86% of all operations), while only 5 patients had colostomies.
  • CONCLUSION: Preoperative stent placement in acute colonic obstruction is minimally invasive and allows an elective one-stage surgery in most cases.
  • [MeSH-major] Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Intestinal Obstruction / surgery. Neoadjuvant Therapy. Palliative Care. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Colon / pathology. Colostomy. Female. Humans. Male. Middle Aged. Prosthesis Design. Rectum / pathology. Retreatment. Tomography, X-Ray Computed. Treatment Outcome


57. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • We have used quantitative real-time PCR to investigate the expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon tissue samples.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


58. Salim S, Liu B, Mahmoodi M, Asad H, Hou SJ: Tactile-like corpuscles in gastric mucosa: a case report. World J Surg Oncol; 2006;4:39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination of hematoxylin and eosin stained sections reveal tactile corpuscle-like structures in the mucosa adjacent to the main tumor mass.
  • CONCLUSION: This is a rare phenomenon and a literature search revealed only one paper describing such structures in the benign colonic mucosa of a colectomy done for carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 2002 Feb;24(1):39-42 [11803280.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):304-8 [9042794.001]
  • [Cites] Ultrastruct Pathol. 2003 Mar-Apr;27(2):79-86 [12746198.001]
  • [Cites] Am J Dermatopathol. 1989 Feb;11(1):94-5 [2916746.001]
  • [Cites] Acta Neuropathol. 1983;61(3-4):173-7 [6359808.001]
  • [Cites] Rom J Morphol Embryol. 1994 Jan-Jun;40(1-2):19-22 [7640370.001]
  • [Cites] No To Shinkei. 1985 Aug;37(8):799-807 [3000414.001]
  • [Cites] Arch Dermatol Res. 1979 Aug;266(1):43-50 [507928.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1978 Aug 4;379(1):73-83 [150689.001]
  • (PMID = 16822307.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1543630
  •  go-up   go-down


59. Abdul M, Hoosein N: N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol; 2005 Jun;205(3):125-8
Hazardous Substances Data Bank. DIZOCILPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the N-methyl-D-aspartate receptor (NMDAr) and its involvement in cellular proliferation is well-known in tumors of neuronal tissue, such as glioma and neuroblastoma.
  • Of 18 benign prostatic hyperplasia (BPH) specimens, none had stromal NMDAr staining, but 2 had low and 1 had high epithelial NMDAr immunoreactivity.
  • We have also examined the effects of the NMDAr antagonist memantine on the growth of ten human cancer cell lines: four prostate, two breast and four colon.
  • [MeSH-minor] Breast / metabolism. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Colonic Neoplasms. Cysteine / analogs & derivatives. Cysteine / pharmacology. Dizocilpine Maleate / pharmacology. Humans. Immunohistochemistry. Male. Memantine / pharmacology. Prostate / physiology. Prostatic Hyperplasia / physiopathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. MEMANTINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362500.001).
  • [ISSN] 0022-2631
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, N-Methyl-D-Aspartate; 2381-08-0 / cysteine sulfinic acid; 6LR8C1B66Q / Dizocilpine Maleate; K848JZ4886 / Cysteine; W8O17SJF3T / Memantine
  •  go-up   go-down


60. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • Increased maspin expression was also found in three MSI-H colon cancer cell lines, but not in three MSS colon cancer cell lines by RT-PCR and western blot analyses.
  • Intense nuclear maspin immunostaining was seen specifically in MSI-H tumours (p = 0.013), de-differentiated tumours (p = 0.006), and at the invasion front.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


61. Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier PP, Scoazec JY, Sastre X, Ruszniewski P, Bedossa P, Couvelard A: Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP; 2008;9(3):339-45
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion.
  • CONTEXT: Desmoid tumors are rare, benign soft tissue tumors, characterized by the proliferation of fibroblasts in an abundant collagen extra-cellular matrix.
  • Although desmoid tumors do not metastasize, their evolution can be life-threatening due to aggressive local invasion, such as mesentery involvement.
  • CASE REPORT: We herein report a very rare location of sporadic desmoid tumors involving the pancreatic tail, presenting as a cystic lesion.
  • The diagnosis of mucinous cystadenocarcinoma was suspected preoperatively and the patient underwent a splenopancreatectomy with en-bloc resection of the left colonic flexure, duodenojejunal junction and part of the posterior gastric wall.
  • Pathological analysis revealed fibroblastic proliferation arising in musculoaponeurotic structures consistent with a desmoid tumor.
  • Perioperative examination reported gastric and small-bowel invasion.
  • No treatment was given postoperatively to prevent desmoid tumor recurrence.
  • CONCLUSION: Desmoid tumors are very rare in the pancreas and their diagnosis can be difficult, such as in our case where it presented as a cystic lesion.
  • In contrast to intra-abdominal forms, sporadic pancreatic desmoid tumors are more frequent than those associated with familial adenomatous polyposis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469451.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


62. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Stoler DL, Nowak NJ, Matsui S, Wiseman SM, Chen N, Dutt SS, Bartos JD, Loree TR, Rigual NR, Hicks WL Jr, Sait SN, Anderson GR: Comparative genomic instabilities of thyroid and colon cancers. Arch Otolaryngol Head Neck Surg; 2007 May;133(5):457-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic instabilities of thyroid and colon cancers.
  • OBJECTIVES: To assess the forms and extent of genomic instability in thyroid cancers and colorectal neoplasms and to determine if such measurements could explain the generally excellent prognosis of thyroid malignant neoplasms compared with colon carcinoma.
  • DESIGN: Tumor genome analyses.
  • RESULTS: The genomic instability index of 32 thyroid carcinomas, 59 colon carcinomas, and 11 colon polyps was determined by ISSR-PCR; no difference was seen among the 3 groups by this method.
  • Fractional allelic loss rates were comparable in thyroid cancers and colon polyps and lower than FAL rates in colorectal cancers.
  • CONCLUSIONS: Genomic alterations in papillary thyroid carcinoma, such as in benign colon polyps, are principally smaller events detected by ISSR-PCR.
  • With the more aggressive tumor types (ie, anaplastic thyroid and colorectal carcinomas), larger events detected by FAL analysis, aCGH, and SKY were revealed.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Papillary / genetics. Colonic Neoplasms / genetics. Genomic Instability / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Alleles. Biomarkers, Tumor. Chromosomes, Human, Pair 8 / genetics. Humans. Karyotyping. Loss of Heterozygosity / genetics. Point Mutation / genetics. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515504.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16056; United States / NCI NIH HHS / CA / R01 CA 74127
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Nocito A, Hahnloser D: [Indications for laparoscopic colorectal resections--also for cancers?]. Ther Umsch; 2005 Feb;62(2):119-26
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last decade, laparoscopy has dramatically changed colonic surgery.
  • Laparoscopic procedures are applied to the treatment of almost all colonic diseases, including both benign and malignant lesions.
  • Significant benefits can be expected with a laparoscopic approach relative to decreased pain, ileus, length of hospital stay, disability, and possibly, adhesion formation and subsequent bowel obstruction, and improved cosmesis.
  • However, all those benefits are secondary in the treatment of cancer; tumor-free survival must be the primary goal.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756922.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 73
  •  go-up   go-down


65. Tralhão JG, Hoti E, Serôdio M, Laranjeiro P, Paiva A, Abrantes AM, Pais ML, Botelho MF, Castro Sousa F: Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol; 2010 Feb;36(2):125-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer.
  • INTRODUCTION: Although there is general correlation between the TNM stage of colorectal cancer (CRC) and its prognosis, there is often significant variability of tumor behaviour and individual patient outcome, which is unaccounted for by pathologic factors alone.
  • Our aim was to estimate perioperative tumor cell dissemination in patients with primary or CRC liver metastases as a possible factor influencing the outcome.
  • Eighteen patients had histologically proven CRC (50% rectal, 44% colonic, 6% colonic and rectal).
  • The remaining six patients who underwent colon or liver resection for benign conditions, acted as the control group.
  • Blood samples were taken before the surgical incision (T0), immediately after tumor resection (T1) and at the end of the surgical intervention (T2).
  • CONCLUSIONS: This study demonstrates no differences in the detected circulating numbers of tumor cells at different stages of surgical intervention.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19646840.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Oishi K, Fukuda S, Sakimoto H, Eto T, Takahashi M, Nishida T: Angiomyolipoma of the colon: report of a case. Surg Today; 2009;39(11):998-1001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiomyolipoma of the colon: report of a case.
  • Angiomyolipomas are benign mesenchymal tumors mostly arising from the kidney.
  • Angiomyolipoma of the colon is extremely rare.
  • Here we report the findings of a 51-year-old man who presented with a submucosal tumor covered with normal mucosa and hemorrhage in the descending colon.
  • He underwent a partial resection of the descending colon.
  • A histopathological examination showed that the tumor of 5.7 cm in diameter included smooth muscle (spindle cell type), mature adipose tissue, and vessels, and therefore a diagnosis of angiomyolipoma was made.
  • A submucosal type of angiomyolipoma of the colon is extremely rare.
  • When colonoscopy shows a submucosal tumor of the colon with hemorrhage, angiomyolipoma should be considered.
  • If an angiomyolipoma of the colon is large, surgical resection should be considered as a treatment option due to the risk of hemorrhage.
  • [MeSH-major] Angiolipoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882325.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Radovanović D, Stevanović D, Pavlović I, Jasarović D, Mitrović N, Ilić I: [Gastrointerstinal stromal tumors of the stomach--case reports]. Med Pregl; 2008 Jul-Aug;61(7-8):409-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointerstinal stromal tumors of the stomach--case reports].
  • INTRODUCTION: Gastrointestinal stromal tumors are the most common mesenchimal tumors of the gastrointestinal tract.
  • The first patient was 59 years old male, with preoperatively diagnosed colonic cancer.
  • Intraoperatively besides the transverse colon cancer, we found intramural gastric tumor.
  • The immunohystochemical analysis of gastric tumor proves benign GIST.
  • The endoscopic ultrasound showed intramural tumor of the anterior gastric wall, with a visible blood vessel bleeding during endoscopy.
  • DISCUSSION: In the cases with inadequate preoperative diagnoses, the level of resection procedure is based on the size of tumor and the presence of necrosis and bleeding inside the tumor.
  • Tumors larger than 5 cm in diameter with signs of necrosis and bleeding are parameters of malignant nature of GIST, therefore demanding a radical surgical treatment.
  • CONCLUSION: The surgical resection is a treatment of choice for gastrointestinal stromal tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097381.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


68. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol; 2007 Sep;34(9):693-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its utility in cutaneous epithelial tumors has never been studied.
  • METHODS: Immunohistochemical staining of CD23 was performed in a total of 131 cases of apocrine, eccrine, follicular and other cutaneous non-lymphoid tumors.
  • RESULTS: CD23 expression was detected in all benign apocrine tumors and in half of benign eccrine tumors, particularly those derived from secretory coils.
  • CD23 staining was seen in 42% (8/19) of microcystic adnexal carcinoma (MAC), while no staining was observed in tumor cells of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma and syringoma.
  • In addition, CD23 reacted diffusely with cutaneous mucinous eccrine carcinoma in a manner similar to breast or colonic adenocarcinoma.
  • CONCLUSION: CD23 appears to be a reliable immunohistochemical marker of the eccrine/apocrine secretory coil and helpful in identifying sweat gland tumors of such origin.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Receptors, IgE / metabolism. Sweat Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696916.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


69. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • The tissue microarrays also included 15 different benign tissues.
  • There were 13 napsin A-positive/thyroid transcription factor-1-negative and 2 thyroid transcription factor-1-positive/napsin A-negative tumors, increasing the number of cases that were positive with at least one of the markers to 81 (85%) of 95.
  • The limited number of neuroendocrine tumors tested was napsin A negative.
  • All squamous cell carcinomas, adenocarcinomas of the colon, pancreas and breast, and mesotheliomas were negative for both markers.
  • Of the renal tumors, napsin A was positive in most of papillary renal cell carcinomas (79%), about one third (34%) of clear cell renal cell carcinomas, and in a single case of chromophobe renal cell carcinoma (3%).
  • As expected, all renal tumors were thyroid transcription factor-1 negative, and all thyroid tumors, except for one papillary carcinoma, were thyroid transcription factor-1 positive.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-major] Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


70. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL: Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg; 2006 Nov;244(5):792-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis that is necessary for wound healing and also promotes tumor growth.
  • It is anticipated that plasma levels would increase after major surgery and that such elevations may facilitate tumor growth.
  • METHODS: Colorectal resection for cancer (n = 139) or benign pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.
  • RESULTS: The mean preoperative VEGF level of the cancer patients was significantly higher than baseline level of benign colon patients.
  • CONCLUSION: As a group colon cancer patients prior to surgery have significantly higher mean VEGF levels than patients without tumors.
  • [MeSH-major] Colectomy. Colonic Diseases / surgery. Gastric Bypass. Minimally Invasive Surgical Procedures. Obesity, Morbid / surgery. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1105-9 [11488797.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Transfusion. 1999 Oct;39(10):1078-83 [10532601.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1264-70 [11071473.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1133-42 [12376368.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):271-4 [12807238.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1187-95 [14513066.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] J Surg Res. 2003 Nov;115(1):113-20 [14572781.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Aug;90(8):1245-50 [2811843.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):956-64 [9528841.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Clin Sci (Lond). 1998 Apr;94(4):395-404 [9640345.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1419-24 [9769380.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Chest. 1998 Dec;114(6):1668-75 [9872204.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):477-81 [10215047.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4804-7 [10519388.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Int J Obes (Lond). 2005 Nov;29(11):1308-14 [15953938.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [CommentIn] Ann Surg. 2007 Jul;246(1):160-1; author reply 161 [17592305.001]
  • (PMID = 17060773.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1856599
  •  go-up   go-down


71. Hornick JL, Fletcher CD: Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol; 2005 Jul;29(7):859-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign peripheral nerve sheath tumors are uncommon in the gastrointestinal tract, and perineuriomas have not previously been reported to occur at this anatomic location.
  • The remaining 2 cases were submucosal masses, one each located in the colon and jejunum.
  • Of the mucosal polyps, six were located in the rectosigmoid or sigmoid colon and one each was detected in the descending colon and transverse colon.
  • The colonic and jejunal masses measured 3 cm and 4.5 cm, respectively.
  • The lesions had a fine collagenous stroma, demonstrated irregular borders with the adjacent lamina propria, and entrapped colonic crypts.
  • The colonic submucosal tumor was microscopically well circumscribed, whereas the jejunal perineurioma showed focal infiltration through the muscularis propria into the subserosa.
  • The stroma was collagenous in the colonic tumor and predominantly myxoid in the jejunal tumor.
  • All tumors except one were positive for epithelial membrane antigen (EMA); 4 of 10 expressed claudin-1 and 2 of 10 expressed CD34.
  • All tumors were negative for S-100 protein, glial fibrillary acidic protein, neurofilament protein, smooth muscle actin, desmin, caldesmon, KIT, and pan-keratin.
  • Electron microscopy was performed on the tumor lacking EMA expression, revealing typical features of perineurioma, namely, spindle cells with long bipolar cytoplasmic processes and prominent pinocytotic vesicles, surrounded by discontinuous basal lamina.
  • No tumor recurred.
  • In summary, perineuriomas may arise in the intestine, most often as intramucosal lesions detected as colorectal polyps with distinctive histologic features including entrapment of colonic crypts.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Oct;30(10):1337-9 [17001168.001]
  • (PMID = 15958849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 26
  •  go-up   go-down


72. Agaimy A, Stoehr R, Vieth M, Hartmann A: Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations. Am J Surg Pathol; 2010 Nov;34(11):1663-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.
  • Colorectal fibroblastic polyp and intramucosal perineurioma are 2 synonyms for a recently described benign mucosal lesion with a predilection for the rectosigmoid colon.
  • All lesions represented asymptomatic solitary polyps (mean size 3.5 mm) localized predominantly in the rectosigmoid colon (81%).
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Epithelial Cells / pathology. Fibroblasts / pathology. Intestinal Mucosa / pathology. Mutation. Nerve Sheath Neoplasms / pathology. Proto-Oncogene Proteins B-raf / genetics. Stromal Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962618.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


73. Sidani SM, Tawil AN, Sidani MS: Extraction of a large self-amputated colonic lipoma: A case report. Int J Surg; 2008 Oct;6(5):409-11
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of a large self-amputated colonic lipoma: A case report.
  • Despite being the most common benign tumor of nonepithelial origin in the colon, colonic lipomas are nonetheless considered a rare occurrence.
  • The minority of patients presenting with symptomatic colonic lipoma are generally treated with resection.
  • We report a case of a symptomatic patient who, on presentation, was found to have a partially obstructing, self-amputated colonic mass on colonoscopy, requiring endoscopic fragmentation to extrude what was later histologically diagnosed to be a lipoma.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopes. Colonoscopy / methods. Lipoma / pathology. Lipoma / surgery
  • [MeSH-minor] Barium Sulfate. Colectomy / methods. Enema / methods. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947813.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


74. Emanuel P, Pertsemlidis DS, Gordon R, Xu R: Benign hybrid perineurioma-schwannoma in the colon. A case report. Ann Diagn Pathol; 2006 Dec;10(6):367-70
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hybrid perineurioma-schwannoma in the colon. A case report.
  • Colonoscopy and computed tomography scan revealed an obstructing colonic mass, causing intussusception and pneumatosis of the descending/upper sigmoid colon and necessitating an emergency left hemicolectomy.
  • Gross examination revealed a 4.9-cm obstructing mass in the sigmoid colon extending through the muscularis propria.
  • Based upon the histopathology, immunophenotype, and ultrastructure, this tumor was classified as a benign hybrid perineurioma-schwannoma, a counterpart to the tumor described in the soft tissue.
  • This is the first case report of hybrid perineurioma-schwannoma in the colon.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Nerve Sheath Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Anastomosis, Surgical. Biomarkers, Tumor / analysis. Colon / surgery. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126257.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Sieren LM, Collins JN, Weireter LJ, Britt RC, Reed SF, Novosel TJ, Britt LD: The incidence of benign and malignant neoplasia presenting as acute appendicitis. Am Surg; 2010 Aug;76(8):808-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of benign and malignant neoplasia presenting as acute appendicitis.
  • We sought to review our experience with neoplasia presenting as appendicitis.
  • Ten patients (7.1%) were diagnosed with neoplasia on final pathology, including four women and six men with a mean age of 46.9 years and mean duration of symptoms of 12.6 days.
  • Final pathology revealed four colonic adenocarcinoma; three mucinous tumors; one carcinoid; one endometrioma; and one patient had a combination of a mucinous cystadenoma, a carcinoid tumor, and endometriosis of the appendix.
  • Colonic and appendiceal neoplasia are not unusual etiologies of appendicitis.

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726408.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z, Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2835-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results.
  • PURPOSE: Gene expression profile (GEP)-based classification of colonic diseases is a new method for diagnostic purposes.
  • EXPERIMENTAL DESIGN: Total RNA was extracted, amplified, and biotinylated from frozen colonic biopsies of patients with colorectal cancer (n=22), adenoma (n=20), hyperplastic polyp (n=11), inflammatory bowel disease (n=21), and healthy normal controls (n=11), as well as peripheral blood samples of 19 colorectal cancer and 11 healthy patients.
  • [MeSH-minor] Adenoma / blood. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Case-Control Studies. Chi-Square Distribution. Colonic Polyps / blood. Colonic Polyps / genetics. Colonic Polyps / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Inflammatory Bowel Diseases / blood. Inflammatory Bowel Diseases / pathology. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


77. Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN: New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol; 2005 Dec 28;11(48):7671-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New tumor-associated antigen SC6 in pancreatic cancer.
  • AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb) in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases.
  • Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls.
  • Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer and 6 severe necrotic pancreatitis patients.
  • The levels in most malignant and benign cases were within the normal upper limit.
  • Decreased expression of SC6-Ag in sera was significantly related to tumor differentiation.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437697.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  • [Other-IDs] NLM/ PMC4727239
  •  go-up   go-down


78. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • In addition, biopsies have been taken from the adjacent healthy colon mucosa at least 5 cm from the lesion in each patient.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • The index of Ki-67 expression in healthy colon mucosa at the patients with cholecystectomy was 37,5 +/- 1,8% (p < 0,05) as compared to 31,36 +/- 1,9 at the patients without cholecystectomy.
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


79. Pasquini P, Baiocchini A, Falasca L, Annibali D, Gimbo G, Pace F, Del Nonno F: Mucosal Schwann cell "Hamartoma": a new entity? World J Gastroenterol; 2009 May 14;15(18):2287-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma is a well-described, benign nerve sheath tumor of the soft tissue, but is rare in the gastrointestinal tract.
  • In this report, we describe the clinicopathologic and immunohistochemical features of a distinctive neural mucosal polyp composed of a diffuse cellular proliferation of uniform bland spindled cells in the lamina propria that entraps the colonic crypts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):797-802 [15728600.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1310-5 [16160473.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):781-7 [19065103.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):846-55 [11420455.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Pathol Res Pract. 2002;198(9):605-13 [12440783.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1275-8 [14750649.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):257-64 [3126126.001]
  • [Cites] J Clin Gastroenterol. 1994 Jan;18(1):13-8 [8113577.001]
  • [Cites] Histopathology. 1995 Oct;27(4):355-60 [8847066.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • (PMID = 19437573.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2682248
  •  go-up   go-down


80. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Minimally Invasive Surgical Procedures / methods. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


81. Cosme A, Tejada A, Bujanda L, Vaquero M, Elorza JL, Ojeda E, Goikoetxea U: Littoral-cell angioma of the spleen: a case report. World J Gastroenterol; 2007 Dec 28;13(48):6603-4
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Littoral-cell angioma (LCA) is a primary splenic vascular tumor that arises from the normal littoral cells lining the sinus channels of the splenic red pulp.
  • A 76-year-old man with a 2-wk history of weight loss, abdominal pain and changes in bowel habits was admitted to our hospital.
  • Our case was associated with a serrated colonic adenoma.
  • LCA is a benign vascular tumor of the spleen that needs to be included in the differential diagnosis of multiple splenic nodules.

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18161935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers; 0 / CD68 antigen, human
  • [Other-IDs] NLM/ PMC4611304
  •  go-up   go-down


82. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


83. Bianchi PP, Ceriani C, Montorsi M: [Laparoscopic surgery of colon cancer. State of art and literature review]. Ann Ital Chir; 2006 Jul-Aug;77(4):289-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery of colon cancer. State of art and literature review].
  • [Transliterated title] La chirurgia laparoscopica nel tumore del colon. Stato dell'arte e revisione della letteratura.
  • Despite reduced morbidity and improved convalescence after laparoscopic surgery for benign disorders, surgeons have been sceptical about similar advantages of laparoscopic colectomy for cancer.
  • The safety of the procedure has been questioned because of early reports of port-site metastases and there has been uncertainty about whether minimally invasive surgery for colonic malignancies would achieve adequate oncologic resection.
  • Open surgical resection of the primary tumor, until just recently, has been widely considered the most effective treatment of colon cancer.
  • The adherence to the principles of complete abdominal exploration, high ligation of mesenteric vessels, lymphnodal clearance and adequate bowel resection margins is essential.
  • Several randomized trials were initiated in the early 1990s to compare the short- and long-term outcomes of patients undergoing minimally invasive and conventional open surgery for colon cancer.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparoscopy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139955.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 21
  •  go-up   go-down


84. Demirbaş T, Güler N, Calişkan C, Gürcü B, Doğanavşargil B, Korkut M: Mechanical bowel obstruction due to colonic hemangioma: report of a case. Turk J Gastroenterol; 2006 Dec;17(4):305-7
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanical bowel obstruction due to colonic hemangioma: report of a case.
  • Colon hemangiomas are rare benign vascular lesions which are usually seen in teenagers.
  • Colonic hemangiomas are occasionally found in the rectosigmoid area.
  • A 62-year-old male patient was admitted to the hospital with the complaints of mechanical bowel obstruction.
  • The radiological imaging techniques revealed a transverse colon tumor.
  • The pathologic examination revealed cavernous hemangioma of the transverse colon.
  • This report describes a very rare case of bowel obstruction due to colonic hemangioma.
  • [MeSH-major] Colonic Neoplasms / pathology. Hemangioma / pathology. Intestinal Obstruction / etiology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205412.001).
  • [ISSN] 1300-4948
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


85. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem; 2010 Mar;58(3):277-85
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synthesis and degradation of the secosteroid occurs not only in the kidney but also in normal tissue or malignant extrarenal tissues such as the colon.
  • Because 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24A1) is considered to be the main enzyme determining the biological half-life of 1,25-D(3), we have examined expression of the CYP24A1 mRNA (by real-time RT-PCR) and protein (by immunohistochemistry) in normal human colon mucosa, colorectal adenomas, and adenocarcinomas in 111 patients.
  • Although 76% of the normal and benign colonic tissue was either completely devoid of or expressed very low levels of CYP24A1, in the majority of the adenocarcinomas (69%), the enzyme was present at high concentrations.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. Steroid Hydroxylases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Colon / enzymology. Female. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Ki-67 Antigen / biosynthesis. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptors, Calcitriol / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vitamin D3 24-Hydroxylase

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2000 May;127(5):717-22 [10788778.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1581-9 [15905206.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6158-65 [11012668.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):847-52 [11075874.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):888-94 [11158062.001]
  • [Cites] Steroids. 2001 Mar-May;66(3-5):409-22 [11179750.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 27;285(4):1012-7 [11467853.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1583-8 [12352462.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):31-41 [16145679.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94 [16236494.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [16180015.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1424-33 [16247453.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):415-24 [16556015.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1819-28 [16708384.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1119-26 [17182978.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 [18089708.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Mol Aspects Med. 2008 Dec;29(6):388-96 [18755215.001]
  • [Cites] Recent Results Cancer Res. 2003;164:239-46 [12899526.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38084-93 [12867411.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):236-41 [14760115.001]
  • [Cites] J Cutan Pathol. 2004 Mar;31(3):224-31 [14984574.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):693-702 [15077124.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):985-9 [15208365.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Steroids. 1990 Sep;55(9):395-8 [2281516.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24673-8 [7929139.001]
  • [Cites] J Invest Dermatol. 1997 Apr;108(4):513-8 [9077483.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 May;62(1):21-8 [9366495.001]
  • [Cites] Endocrinology. 1999 May;140(5):2071-6 [10218956.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):82-90 [10337990.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20604-11 [15788398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7 [16103450.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):977-84 [10891358.001]
  • (PMID = 19901270.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2825493
  •  go-up   go-down


86. Pickhardt PJ, Kim DH, Taylor AJ, Gopal DV, Weber SM, Heise CP: Extracolonic tumors of the gastrointestinal tract detected incidentally at screening CT colonography. Dis Colon Rectum; 2007 Jan;50(1):56-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracolonic tumors of the gastrointestinal tract detected incidentally at screening CT colonography.
  • PURPOSE: The aim of this article is to report our experience with incidental detection of extracolonic tumors of the gastrointestinal tract identified prospectively at screening CT colonography.
  • Following cathartic preparation and colonic distention, supine and prone multidetector CT scans were obtained with thin-collimation low-dose technique without intravenous contrast.
  • Tumor locations included ileum (n = 3), stomach (n = 3), jejunum (n = 2), and appendix (n = 2).
  • Mean tumor size was 2.2 (range, 0.8-3.4) cm.
  • Final diagnoses were benign in all cases and included lipoma (n = 3), small-bowel hamartoma (n = 2), appendiceal mucinous cystadenoma (n = 2), gastric leiomyoma (n = 1), small-bowel lymphangioma (n = 1), and gastric fundic gland polyp (n = 1).
  • CONCLUSIONS: Incidental extracolonic tumors of the gastrointestinal tract detected at screening CT colonography were all asymptomatic and benign but often prompted more invasive workup.
  • Although the incidence of these tumors was relatively low, widespread population screening with CT colonography would result in new surgical referrals for these findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115333.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Coffin CM, Spilker K, Zhou H, Lowichik A, Pysher TJ: Frozen section diagnosis in pediatric surgical pathology: a decade's experience in a children's hospital. Arch Pathol Lab Med; 2005 Dec;129(12):1619-25
MedlinePlus Health Information. consumer health - Children's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequent indications included questions related to neoplasms (tumor detection, specimen adequacy, triage, classification, and margins) and suspected Hirschsprung disease.
  • The major discrepancies included tumor, ganglion cell, or organism detection.
  • The minor discrepancies involved sampling error, reclassification of benign or malignant neoplasms without clinical consequences, tumor typing or grading, and ganglion cell identification without clinical impact.
  • Deferrals in 718 FSs (25% deferral rate) included tumor classification from generic to specific, identification of organisms, and evaluation of lymph node biopsies for lymphoma.
  • Evaluation of colonic biopsies for ganglion cells is a diagnostic pitfall.
  • Traditional definitions of deferred and discordant FS diagnoses should be refined to reflect the increasing use of adjunct techniques, especially in tumor classification.
  • These findings emphasize that, in children and adolescents, most FSs are performed for tumor classification, triage, detection, and specimen adequacy, and for possible Hirschsprung disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16329734.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Jiang B, Ren T, Dong B, Qu L, Jin G, Li J, Qu H, Meng L, Liu C, Wu J, Shou C: Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol; 2010 Sep;177(3):1095-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients.
  • Tumor-associated antigens, which induce the generation of autoantibodies, are useful as cancer biomarkers in early detection and prognostic prediction of cancer.
  • To isolate a novel cancer marker, we used serum antibodies from colon cancer patients to screen a phage display peptide library.
  • A positive peptide 249C (VPLYSNTLRYGF) that could specifically react with serum from colon cancer patients was isolated, and the corresponding antigen-human arrest defective 1 (ARD1A), which shares an identical LYSNTL motif with 249C, was identified.
  • Using ELISA and immunohistochemistry, we found anti-ARD1A antibody levels in serum from patients with colon cancer were significantly higher than those in healthy volunteers (P < 0.001), and ARD1A expression was detected in 84.1% (227/270) of colon cancer tissues compared with 22.7% (55/242) of matched noncancerous tissues (P < 0.001) and 4.8% (2/42) of benign lesions (P < 0.001).
  • These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer.
  • [MeSH-major] Acetyltransferases / blood. Antigens, Neoplasm / blood. Autoantibodies / blood. Colonic Neoplasms / blood. Colonic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / isolation & purification. Blotting, Western. Cell Line, Tumor. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Epitopes / isolation & purification. Humans. Kaplan-Meier Estimate. Middle Aged. N-Terminal Acetyltransferase A. N-Terminal Acetyltransferase E. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31132-40 [15994306.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17749-57 [15755738.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1131-6 [16279846.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4350-60 [16518407.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10677-82 [17108104.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):619-26 [17998402.001]
  • [Cites] Cancer Lett. 2008 Jun 8;264(1):83-92 [18325661.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Histopathology. 2009 Feb;54(3):309-18 [19236507.001]
  • [Cites] Biochem J. 2009 Apr 1;419(1):133-9 [18973474.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):909-15 [19287988.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15209-14 [11742062.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):636-43 [12079511.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2572-82 [15352232.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):16-20 [7505195.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4656-62 [15536075.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):433-43 [15496142.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 20639454.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  • [Other-IDs] NLM/ PMC2928944
  •  go-up   go-down


90. Maruthachalam K, Lash GE, Shenton BK, Horgan AF: Tumour cell dissemination following endoscopic stent insertion. Br J Surg; 2007 Sep;94(9):1151-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour cell dissemination following endoscopic stent insertion.
  • METHODS: Peripheral venous blood samples were obtained before and after colonoscopy (38 patients) or colonic stent insertion (20).
  • Twenty patients undergoing colonoscopy for benign conditions served as controls.
  • CONCLUSION: Endoscopic insertion of colonic stents but not staging colonoscopy results in increased levels of CK20 mRNA in the peripheral circulation.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / surgery. Keratin-20 / blood. Neoplastic Cells, Circulating / metabolism. Stents / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • [CommentIn] Br J Surg. 2008 Jan;95(1):127-8; author reply 128 [18161907.001]
  • (PMID = 17541987.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / RNA, Messenger
  •  go-up   go-down


91. Pulitzer M, Xu R, Suriawinata AA, Waye JD, Harpaz N: Microcarcinoids in large intestinal adenomas. Am J Surg Pathol; 2006 Dec;30(12):1531-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Composite adenoma-carcinoid tumors are rare colorectal lesions consisting of intermingled adenomatous and carcinoid components.
  • Unlike other mixed endocrine-glandular colorectal neoplasms, which are generally malignant, their glandular component is histologically benign and their natural history is favorable.
  • We present 4 cases of colonic adenomas containing microcarcinoids, a hitherto undescribed lesion that is either a precursor of composite adenoma-carcinoids or a related but independent entity.
  • The cases, identified among our surgical and consultation files, were endoscopically routine sessile polyps removed from 4 otherwise normal individuals, 3 from the cecum and 1 from the distal colon.
  • The patients' clinical course was benign on the basis of 2 years' median follow-up (range, 6 mo to 10 y).
  • Two patients with incomplete polypectomies underwent hemicolectomy revealing no residual endocrine neoplasia.
  • Awareness of microcarcinoids in colonic adenomas should help avert potential diagnostic pitfalls posed by their pleomorphism, basal location, and infiltrative patterns, and may help clarify their natural history and possible relationship to composite glandular-carcinoid tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoid Tumor / pathology. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122508.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE: Tumors associated with superficial thrombophlebitis. Vasa; 2009 May;38(2):167-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors associated with superficial thrombophlebitis.
  • BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early tumor detection.
  • RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant tumor: breast cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .
  • Superficial thrombophlebitis may have been associated in four cases (2.9%) with a benign tumor.
  • CONCLUSIONS: Breast, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588305.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


93. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis.
  • Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003).
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • In combination with cytokeratin 7 and Hep Par1, N-cadherin is a reliable tool for the histopathological diagnosis of primary hepatic tumors.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


94. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH: Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res; 2007 Jun 15;67(12):5600-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
  • Colon cancer-specific antigen (CCSA)-3 and CCSA-4 are novel colon cancer markers identified by focused proteomic analysis of nuclear structural proteins.
  • Serum samples from 107 subjects undergoing colonoscopy, 28 subjects with colorectal cancer, and 125 subjects with benign disease or other types of cancer were evaluated.
  • Individuals who underwent colonoscopy were classified into mutually exclusive categories, including normal colon, hyperplastic polyp, nonadvanced adenoma, and advanced adenoma.
  • [MeSH-major] Adenocarcinoma / blood. Adenoma / blood. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH. Cancer Res. 2013 Jan 15;73(2):1034 [23271721.001]
  • (PMID = 17575123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / colon-specific antigen
  •  go-up   go-down


95. Leinung S, Möbius C, Udelnow A, Hauss J, Würl P: Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. Eur J Surg Oncol; 2007 May;33(4):508-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience.
  • RESULTS: We treated 597 patients with soft tissue tumors.
  • Open biopsy revealed soft tissue sarcoma in 318 cases, benign mesenchymal tumor in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
  • The primary carcinomas were lung cancer in 26 patients, breast cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
  • CONCLUSIONS: In our collective with soft tissue tumor, 50% of the patients had the diagnosis of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a benign tumor.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081724.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Kupcsulik P: [Laparoscopic colorectal surgery]. Magy Seb; 2006 Apr;59(2):79-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery have earned a firm place in the treatment of benign colon diseases.
  • Concerning the treatment of malignant colorectal tumors the value of LAP surgery has evoked controversial assessments.
  • Independent factors like tumor stage, R0 resection, histological parameters and surgeon determine prognosis.
  • Previous discussions about port site metastases and tumor cell dissemination by pneumoperitoneum have silenced.
  • Several randomized studies have proven the short term superiority of LAP resection in term of postoperative pain management, bowel movement, hospital stay and rehabilitation over open methods.
  • Newly, more multicentric randomized trials were conducted on late results of LAP surgery for malignant colorectal tumors which has been proved nonsignificantly better or equal to conventional surgery.
  • [MeSH-minor] Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Humans. Prognosis. Quality of Life. Randomized Controlled Trials as Topic. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784030.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 88
  •  go-up   go-down


97. Herawi M, Leppert JT, Thomas GV, De Kernion JB, Epstein JI: Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: support for "seed and soil" hypothesis of bladder recurrence. Urology; 2006 Apr;67(4):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To explore the underlying mechanism of tumor regrowth in cases of noninvasive urothelial carcinoma that recur in unusual anatomic locations.
  • One had presented as an implant in the peritoneal investment of the bladder dome and the other as multiple implants growing on the benign surface of the colonic mucosa of an orthotopic neobladder distant from the anastomosis site.
  • Although the urinary bladder was free of neoplastic changes at nephroureterectomy, both patients also developed several papillary tumors within the bladder shortly after the removal of the kidney.
  • CONCLUSIONS: After clinicopathologic correlation, the mode of tumor spread in these cases was best explained by the "seeding/implantation" theory.
  • The urothelial tumor cells in each of these cases demonstrated the ability to implant themselves not only in the urothelium of the bladder but also in the colonic mucosa of a constructed neobladder and on the peritoneal surface.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Neoplasm Recurrence, Local / etiology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged, 80 and over. Colon / surgery. Female. Humans. Ileum / surgery. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566991.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


99. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • METHODS: The expression of XAF1 in four human colon cancer cell lines (Colo205, Colo320, SW1116, LoVo) and in samples from 70 patients with CRC was analyzed by reverse transcriptase-polymerase chain reaction.
  • RESULTS: A low concentration of XAF1 mRNA was detectable in the three colon cancer cell lines other than Colo205, which showed the strongest expression of XAF1.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


100. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutation frequency in carcinomas, benign and malignant polyps was 43, 49, and 69%, respectively.
  • In patients with colorectal carcinoma the mutation frequency in the K-ras gene was not associated with disease onset age, location, and the extent of tumor differentiation while it was associated with the stage of tumor process.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down






Advertisement